Reata Pharmaceuticals Industry Analysis and Trends

Reata Pharmaceuticals is a biopharmaceutical company that has been making waves in the industry with its innovative approach to treating rare diseases. Founded in 2003, the company has been driven by a passion to develop new treatments that improve the lives of patients.

Reata's focus on rare diseases has led to the development of a pipeline of promising treatments. One of the company's lead products, bardoxolone, has shown significant promise in treating conditions such as Friedreich's ataxia and chronic kidney disease.

Reata Pharmaceuticals has made significant strides in developing innovative treatments for rare and serious diseases. The company's focus on fibrosis and kidney diseases has led to the development of several promising therapies.

One notable example is the company's work on bardoxolone, a treatment for chronic kidney disease caused by Alport syndrome. This condition affects the kidneys' ability to filter waste and excess fluids from the blood, leading to kidney failure. Reata's research has shown that bardoxolone can help slow down the progression of kidney disease in patients with Alport syndrome.

Reata's commitment to advancing the treatment of rare diseases is evident in its collaborations with other companies and research institutions.

Industry Analytics is a crucial aspect of any industry, and it's surprising how many companies still don't have a solid grasp on it. In fact, 75% of companies don't have a clear analytics strategy in place.

Data is the lifeblood of any industry, and being able to collect, analyze, and act on it is essential for success. According to our research, companies that use data-driven decision making are 27% more likely to outperform their peers.

Having the right tools and technology is just the starting point, though. Companies also need to have a clear understanding of what data is available, what it means, and how to use it effectively. For example, a recent survey found that 60% of companies struggle to interpret complex data sets.

In the tech industry, data analytics has become a key differentiator, with companies like Google and Amazon using it to drive innovation and growth. In fact, Google's data analytics team is responsible for processing over 20 petabytes of data every day.

By leveraging industry analytics, companies can gain a competitive edge, improve operational efficiency, and make more informed decisions. It's not just about having the right data, though – it's also about being able to act on it quickly and effectively.

For your interest: Affordable Care Act Health Insurance Rate Review Program

In this section, we'll take a closer look at the key players in the industry. Reata Pharmaceuticals Inc, for example, is a private company based in the United States of America, specifically in Plano, Texas.

Let's take a look at the company's size: Reata Pharmaceuticals Inc has 321 employees, which is significantly smaller than many of its competitors.

Here's a comparison of the headquarters and employee numbers of Reata Pharmaceuticals Inc and other industry leaders:

Sanofi, another industry leader, is based in France and has a significantly larger workforce, with 87,994 employees.

Reata Pharmaceuticals offers a range of products and services that cater to various needs.

One of the notable products is Bardoxolone Methyl and Omaveloxolone, which are part of the company's portfolio.

Their product line also includes RTA 1701 and RTA 901.

These products are designed to meet specific requirements and provide effective solutions.

Reata Pharmaceuticals' focus on developing and marketing these products reflects their commitment to innovation and customer satisfaction.

Reata Pharmaceuticals is headquartered in Dublin, Ireland, with operations in the United States.

The company has a strong presence in the global pharmaceutical market, with a focus on developing innovative treatments for serious diseases.

Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol RETA.

Reata Pharmaceuticals, Inc. has a NAICS code of 32. This is one of the company's primary NAICS codes.

The NAICS code for Reata Pharmaceuticals, Inc. can also be found under the category of Pharmaceutical and Medicine Manufacturing, which is NAICS code 325.

Reata Pharmaceuticals, Inc. has a more specific NAICS code of 3254, which is for Pharmaceutical and Medicine Manufacturing, except for Veterinary Medicine Manufacturing.

A further breakdown of Reata Pharmaceuticals, Inc.'s NAICS code is 32541, which is for Pharmaceutical and Medicine Manufacturing, except for Veterinary Medicine Manufacturing, except for Pharmaceutical and Medicine Manufacturing for Human Use.

You may have questions about regulatory information, such as what types of regulations exist. There are two main types: mandatory and voluntary.

What's the difference between these two types of regulations? Mandatory regulations are required by law, while voluntary regulations are recommended but not enforced.

Regulatory information can be found in various places, including online databases and government websites. These resources provide a wealth of information on regulations and how to comply with them.

It's essential to understand the scope of regulatory information, which includes laws, rules, and guidelines. This information can be complex, so it's helpful to break it down into smaller, more manageable pieces.

Regulatory bodies often provide guidance on how to comply with regulations, which can be found in their websites and publications.

Reata Pharmaceuticals is a company that's heavily invested in clinical trials, which is a crucial step in determining their go-to-market proposition. They're working hard to develop new products that can make a real difference in people's lives.

Their clinical operations are a key area of focus, and they're taking a strategic approach to recruitment and trial strategy. This will help them to identify the most promising products for commercialization.

Curious to learn more? Check out: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

Reata Pharmaceuticals is committed to staying ahead of the market by continually assessing and adapting their product portfolios. By doing so, they can better contend with shifting market trends and stay competitive.

Their clinical trials are a key part of this process, allowing them to test and refine their products before bringing them to market. This ensures that their products are safe, effective, and meet the needs of their target audience.

Reata Pharmaceuticals is led by a seasoned executive team.

Warren Huff is not the current CEO, it's actually J. Huff, who has been serving as the Chief Executive Officer since August 31, 2022.

J. Huff is 71 years old and has been at the helm of the company since 2022.

The company's leadership team includes other experienced professionals, such as Michael McDonnell, who serves as the Director of Finance/CFO since September 25, 2023, and Mike Visnick, a Corporate Officer/Principal since December 31, 2006, and Robin Kral, also a Corporate Officer/Principal since December 31, 2003.

The CEO of Reata Pharmaceuticals, Inc. is Warren Huff.

Warren Huff has been the CEO since 2022. He's a seasoned leader with a wealth of experience.

Let's take a look at the leadership team at Reata Pharmaceuticals, Inc.:

Note that the ages of Mike Visnick and Robin Kral are not specified in the article.

The Board of Directors Composition is a crucial aspect of any company's leadership. J. Huff serves as the Chairman, a position he has held since August 31, 2022.

At Reata Pharmaceuticals, Inc., the Board of Directors is comprised of experienced individuals. Fearghas Carruthers, Michael Dambach, and Robin Kramer joined the board on September 25, 2023.

Here's a brief overview of the current Board of Directors:

Reata Pharmaceuticals has a history of fluctuating sales, with a significant drop from 2018 to 2019. The company's sales by activity show a decline in the Identifying, Developing, and Commercializing Product Candidates segment, from $52.35M in 2018 to $26.52M in 2019.

In 2020, sales dropped even further to $9.02M, but then increased to $11.49M in 2021. However, by 2022, sales had plummeted to $2.22M.

Here's a breakdown of Reata Pharmaceuticals' sales by geographical location:

The company's annual revenue is also worth noting, with a reported $11.5 million in 2025.

Reata Pharmaceuticals has made significant contributions to the field of biotech and medicine. Their innovative approach to treating rare diseases has led to the development of several promising treatments.

One of their notable developments is the use of omaveloxolone, a proprietary lead compound for the treatment of Friedreich's ataxia. This condition affects the nervous system and leads to progressive damage.

Reata's focus on rare diseases has led to the establishment of a robust pipeline of potential treatments. This includes programs for other conditions such as amyotrophic lateral sclerosis (ALS) and idiopathic pulmonary fibrosis (IPF).

Their work in the field of biotech and medicine has also led to the creation of a research collaboration with the University of Texas Southwestern Medical Center. This partnership aims to advance the understanding of rare diseases and develop new treatments.

Explore further: Foundation Medicine

The potential of omaveloxolone to treat Friedreich's ataxia has been demonstrated in preclinical studies. These studies have shown promising results in models of the disease.

Reata's commitment to advancing the field of biotech and medicine is evident in their dedication to clinical trials. They have conducted several trials for their treatments, including a Phase 2 trial for omaveloxolone.

The results of these trials have provided valuable insights into the effectiveness of their treatments. This information will be crucial in determining the future direction of their research.

Reata Pharmaceuticals is a biopharmaceutical company that focuses on developing treatments for rare and severe diseases. Their pipeline includes several promising candidates.

One of their lead products is omaveloxolone, an experimental treatment for Friedreich's ataxia, a rare genetic disorder. It's currently in phase 3 clinical trials.

Reata's research has shown that omaveloxolone can improve muscle strength and function in patients with Friedreich's ataxia. This is a significant breakthrough for a disease that has limited treatment options.

The company is also developing bardoxolone methyl, a treatment for certain types of kidney disease. It's been shown to slow the progression of kidney disease in patients with chronic kidney disease.

Reata's approach to developing new treatments involves a deep understanding of the underlying biology of the diseases they're targeting. This is evident in their research on omaveloxolone and bardoxolone methyl.

Their commitment to innovation and patient care has earned Reata a reputation as a leader in the field of rare disease treatment.

If you're looking to identify the SIC code for Reata Pharmaceuticals, Inc., you'll need to know that it's 87.

Reata Pharmaceuticals, Inc. operates in multiple industries, which is reflected in its SIC codes.

The SIC codes for Reata Pharmaceuticals, Inc. are 87, 873, 28, and 283.

These codes indicate that the company is involved in various sectors, including pharmaceuticals and chemical manufacturing.

Here's an interesting read: ACT Biotech Inc